Life Science

AI Tailored Precision for Clinical Development

Driven by our quantitative imaging biomarkers, regulated software and clinical expertise, our bespoke end-to-end services for Pharma, Biotech and Medtech provide tailored support throughout the full lifecycle of clinical development, from concept to execution, medical affairs and beyond.

Core Partnership Areas
‍
Gray circle with white number 01 centered inside.
Icon showing two overlapping documents, one with lungs and text lines and a magnifying glass

Retrospective
Clinical Trials

Post-hoc or exploratory analysis of existing clinical trial datasets to uncover new findings and to test or validate existing results.

Light gray circle with the number 02 in white inside.
Clipboard with a user profile icon and a clock symbol indicating time or schedule.

Prospective
Clinical Trials

Prospective analysis, including of baseline cohort characterisation and follow up assessment through  quantitative endpoints for safety, efficacy and MOA.

Light gray circle with white number 03 centered inside.
Gray Earth globe centered on Africa with a plus icon and a menu icon around it.

Real World
Datasets

Brainomix or sponsor-provided Real-World data to test, validate or inform study findings and clinical development strategy.

Light gray circle with white number 04 centered inside.
Icon with two person silhouettes, a DNA strand, and crossed wrench and screwdriver tools.

Bespoke Development of Software or Biomarkers

Creation and validation of novel digital biomarkers and bespoke software for Life Science partners using Brainomix- or Sponsor provided data.

Light grey circle with white number 05 centered inside.
Graph of increasing bar chart with plus sign and upward arrow showing growth or improvement.

Supporting
Treatment Decisions

Brainomix regulatory cleared software can be used as part of go-to-market strategies to support appropriate treatment decisions in the Real World.

Light gray circle with the number 06 centered in white text.
Icon with user silhouette and hand holding a medical cross next to three horizontal lines and dots.

Expert
Clinical Advisory

Design and Review of Protocols, Selection of Endpoints, Interpretation and Dissemination of Study Results.

Life Science Partners. Brainomix's services support a wide array of Life Science companies from across the globe, including biotech start-ups, large pharma partners, and medical device companies.
AstraZeneca logo with stylized abstract icon.BridgeBio Therapeutics logo in white text on a transparent background.Boehringer Ingelheim company logo with stylized building icon in a circle.Endeavor BioMedicines company logo with stylized asterisk symbol and text.Lumosa Therapeutics logo with a stylized tree and Chinese characters above the name.Argenica Therapeutics logo with circular dot pattern to the left of the text.MedtronicAvalyn Pharma logo with a sailboat icon above the text.White text spelling CLARIO with a period on a transparent background.
AstraZeneca logo with stylized abstract icon.BridgeBio Therapeutics logo in white text on a transparent background.Boehringer Ingelheim company logo with stylized building icon in a circle.Endeavor BioMedicines company logo with stylized asterisk symbol and text.Lumosa Therapeutics logo with a stylized tree and Chinese characters above the name.Argenica Therapeutics logo with circular dot pattern to the left of the text.AbbVieMedtronicRemedy Pharmaceuticals text logo in white font on a transparent background.Avalyn Pharma logo with a sailboat icon above the text.White text spelling CLARIO with a period on a transparent background.
Person holding phone showing brain scan with red and yellow markings on the screen.
20+
Leading Life Science partners benefitting from Brainomix insights and expertise.
Person holding a smartphone displaying a colorful brain scan image with data controls.
3.5 Mil
More than 3.5 million scans processed by Brainomix
Close-up of a hospital stretcher wheel with a person walking behind it in a corridor.
18+
Regulatory Clearances for Clinical Use (FDA, CE, ANVISA, and more)
Medical professional reviewing lung scan images and data on a computer screen in an office setting.
350+
Hospital Installations
Person using a smartphone to view a brain scan image with highlighted areas on the screen.
40+
Imaging Biomarkers Available
Evening view of Radcliffe Camera and surrounding historic buildings in Oxford under a clear blue sky.
30+
Countries with Brainomix deployed
Scientist wearing safety glasses uses touchscreen displaying colorful brain scan images.
15
Clinical trials
Doctor discussing medical information on a computer with an elderly couple in a bright office.
5
Phase III clinical trials
Service Offering
Work with Brainomix today to support your clinical development.
01
Specialty imaging support for multi-center clinical trials
02
AI-enhanced cohort evaluation for eligibility adherence and safety assessments
03
Proprietary biomarkers, bespoke development services, and Core Lab analytics
04
Medical and imaging consulting support for trial design, execution, and data interpretation
05
Customizable patient selection software to enrich and standardize study populations
06
Seamless integration into leading CROs to streamline clinical trial and imaging workflows
AI-Powered Quantitative Imaging Biomarkers
Stroke
Lung
Imaging Biomarkers
ASPECTS
Clot Location
Collateral Volume
Ischemic Core Volume
Edema
Perfusion (Core, Penumbra, Mismatch)
Haemorrhage Quantification
CT brain scan with red and yellow outlines highlighting areas in the left hemisphere.
Modality: CT
Automated measure of ASPECTS
CT scan of a brain with a red circle highlighting a clot in a blood vessel near the center.
Modality: CTA
Automated detection and localization of LVO
3D brain scan showing blood vessels in white with an orange highlighted area and a red circle mark.
Modality: CTA
Automated quantification of collaterals
CT brain scan showing red-highlighted area on right side indicating possible abnormality or hemorrhage.
Modality: NCCT, MRI
Automated measure of ischemic core, voxel-by-voxel measurement
Axial brain MRI scan showing an area of orange-highlighted abnormality on the right hemisphere.
Modality: NCCT, MRI
Automated measure of edema/swelling
Brain scan with highlighted regions in green and magenta indicating areas of interest or abnormality.
Modality: CTP, MRI
Automated measure of perfusion metrics
CT brain scan showing a highlighted pink abnormal area in the right hemisphere of the brain.
Modality: NCCT, MRI
Automated measure of blood volume
Imaging Biomarkers
Total Lung Volume
Inflammation
Fibrosis
3D rendering of human lungs and trachea against a black background.
Modality: CT
Measure of total lung volume which correlates with lung physiology measures such as FVC
3D rendering of lungs showing bronchial tubes and damaged tissue on the lower left lung.
Modality: CT
Validated in INBUILD® Phase III Study of Ofev®
Illustration of human lungs showing widespread red patches indicating lung damage or disease.
Modality: NCCT
Shown to prognosticate for mortality and disease progression. Validated in INBUILD® Phase III Study of Ofev®
Clinical Trial Case Studies
Link to image
AstraZeneca
Trial: NCT01629667
Phase: II
Indication: Idiopathic Pulmonary Fibrosis
Treatment: tralokinumab  

Brainomix and AstraZeneca partnered to analyze Phase 2 tralokinumab clinical trial data, leveraging Brainomix’s AI-powered software and biomarkers to uncover novel insights. The output of this partnership has been published in the AJRCCM.
“As key components in AstraZeneca’s strategy to bring new medicines to patients faster and more effectively, data science and AI are transforming R&D. Our collaboration with Brainomix helped us to expand our understanding of the potential that innovative AI approaches can bring to improving the design of clinical trial for patients with Interstitial Lung Disease.”
Dr. Kristoffer Ostridge
Head of Experimental Medicine, AstraZeneca
Link to image
Boehringer Ingelheim
Trial: DROP-FPF (NCT07201922)
Phase: III
Indication: Pulmonary Fibrosis
Treatment: nerandomilast (Jascayd®)

In an industry-first, Boehringer Ingelheim selected Brainomix AI fibrosis biomarkers as the co-primary imaging endpoint for its Phase III trial in pulmonary fibrosis to provide a quantifiable measure of disease progression alongside FVC, a traditional measure of lung function.
“Our goal is simple but profound: learn whether acting earlier can change outcomes for families facing these devastating diseases. Using Brainomix’s advanced HRCT algorithm to define meaningful progression, we aim to generate insights that could transform how and when to intervene.”
Martin Beck
Senior VP and Head of Inflammation, Boehringer Ingelheim
Link to image
Remedy Pharmecuticals
Trial: CHARM (NCT02864953)
‍Phase: III
‍Indication: Large Hemispheric Infarction
‍Treatment: Glyburide

For its Phase 3 study on Glyburide (CIRARA) in large hemispheric infarction, Remedy partnered with Brainomix to perform an analysis of both imaging and clinical data. Brainomix quantified baseline and follow-up images of patients who had been assessed using NCCT, CTP, and MRI modalities using advanced multi-modal AI imaging biomarkers.
“Brainomix imaging and data analysis capabilities really allowed us to explore our data more deeply and clearly than we previously had thought possible. Our partnership was highly productive, insightful and valuable in informing our ongoing clinical development”
Sven Jacobsen
CEO Remedy Pharmecuticals
Link to image
Argenica Therapeutics
Trial: SEANCON (ACTRN12623001110673)
Phase: II
Indication: Acute Ischemic Stroke
Treatment: ARG-007

Brainomix and Argenica Therapeutics have partnered on the ARG-007-002 study. Brainomix AI expertise and analytics are supporting the clinical development of ARG-007 through robust characterization of treatment effect and identification of responsive phenotypes.
“Brainomix expertise and AI-enhanced imaging allows to do more with our clinical trial data, giving us a better indication of treatment effect and allowing us to dig into key biomarkers.”
Liz Dallimore
CEO Argenica Therapeutics
Link to image
Acticor Biotech
Trial: ACTIMIS (NCT03803007)
Phase: I/II
Indication: Acute Ischemic Stroke  
Treatment: glenzocimab

Brainomix and Acticor collaborated on analysis of the Phase Ib/IIa ACTIMIS study in acute ischemic stroke. Brainomix AI imaging analytics were able to further explore treatment efficacy and mechanism of action.
"We are delighted with this collaboration with Brainomix, which enables us to analyze in greater detail the brain images of patients in the ACTIMIS study. Preliminary results show that glenzocimab reduces not only the occurrence of intracranial hemorrhages but also their volume, compared with placebo. These results support the first analyses of ACTIMIS and will be submitted to upcoming international congresses."
Dr Yannick Pletan
Chief Medical Officer and General Manager, Acticor Biotech
Man in blue suit with paisley tie standing outside near stone building with window.
“I have been proud to contribute to our Life Science Partnerships during my time at Brainomix. Our approach is critically focused on delivering sustainable, mutually aligned value to our Partners, and I am confident in our capabilities to work within this ecosystem to make a positive impact on patient outcomes.”
Ross Stewart
Associate Director, Life Sciences
Young woman with long brown hair wearing a purple sleeveless striped top, standing indoors by a window.
Kira joined Brainomix in 2025 as part of the Life Sciences business development team. Before transitioning into industry, she completed a PhD in Molecular Cell Biology at the University of Oxford, studying tumour responses to targeted therapies. At Brainomix, she combines her scientific background with her interest in driving innovation to help forge partnerships that translate AI-driven insights into better clinical outcomes.
Kira Schützenhofer, PhD
Business Development Associate

Ready to transform your clinical development journey?

Join 20+ leading Life Science partners already benefitting from Brainomix insights and expertise.

Get in Touch
Brainomix

Brainomix Limited, First Floor, Seacourt Tower West Way Oxford OX2 0JJ

Brainomix Limited is a company registered in England and Wales at OX2 0JJ. Company Registration No. 07426406

International
AI SolutionsVantageStrokeLung
Clinical EvidenceBrain PublicationsLung Publications
Life SciencesOverview
Content HubNewsCase StudiesPodcasts & VideosEventsPress Releases
CompanyOur StoryLeadership TeamCareersESG
SupportUser ManualsContact UsFAQsMedia Kit
Privacy Policy
YouTubeLinkedIn

Brainomix © 2026. All rights reserved